[go: up one dir, main page]

UA94231C2 - Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли - Google Patents

Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли

Info

Publication number
UA94231C2
UA94231C2 UAA200714106A UAA200714106A UA94231C2 UA 94231 C2 UA94231 C2 UA 94231C2 UA A200714106 A UAA200714106 A UA A200714106A UA A200714106 A UAA200714106 A UA A200714106A UA 94231 C2 UA94231 C2 UA 94231C2
Authority
UA
Ukraine
Prior art keywords
treating
composition
oligonucleotides
same
cell neoplasm
Prior art date
Application number
UAA200714106A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ли-ин Ван
Му-шен Бао
Юн-ли Юй
Original Assignee
Чанчунь Хуапу Байотекнолоджи Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чанчунь Хуапу Байотекнолоджи Ко., Лтд. filed Critical Чанчунь Хуапу Байотекнолоджи Ко., Лтд.
Publication of UA94231C2 publication Critical patent/UA94231C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Данное изобретение относится к способу лечения у млекопитающего В-клеточной опухоли и предусматривает введение эффективного количества композиции, которая содержит олигонуклеотид, который отвечает последовательности SEQ ID NO: 1.
UAA200714106A 2005-05-17 2006-02-13 Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли UA94231C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2005100695764A CN1865275B (zh) 2005-05-17 2005-05-17 对人b细胞肿瘤有治疗作用的人工合成的单链脱氧核苷酸

Publications (1)

Publication Number Publication Date
UA94231C2 true UA94231C2 (ru) 2011-04-26

Family

ID=37424439

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200714106A UA94231C2 (ru) 2005-05-17 2006-02-13 Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли
UAA200714103A UA91057C2 (ru) 2005-05-17 2006-02-13 Олигонуклеотид или его функциональный гомолог, композиция, содержащая его, и способ лечения в-клеточной опухоли

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA200714103A UA91057C2 (ru) 2005-05-17 2006-02-13 Олигонуклеотид или его функциональный гомолог, композиция, содержащая его, и способ лечения в-клеточной опухоли

Country Status (21)

Country Link
US (3) US8133874B2 (ru)
EP (2) EP1883411B1 (ru)
JP (2) JP4837034B2 (ru)
KR (2) KR101294131B1 (ru)
CN (1) CN1865275B (ru)
AU (2) AU2006246897B2 (ru)
BR (2) BRPI0609885A2 (ru)
CA (2) CA2609067A1 (ru)
CY (1) CY1114844T1 (ru)
DK (2) DK1883647T3 (ru)
ES (2) ES2442462T3 (ru)
IL (2) IL187281A (ru)
MX (2) MX2007014146A (ru)
NZ (1) NZ563582A (ru)
PL (2) PL1883647T3 (ru)
PT (2) PT1883647E (ru)
RU (2) RU2413519C2 (ru)
SI (2) SI1883647T1 (ru)
UA (2) UA94231C2 (ru)
WO (2) WO2006122464A1 (ru)
ZA (2) ZA200710312B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2288702A4 (en) * 2008-06-18 2011-06-29 Index Pharmaceuticals Ab COMBINATION THERAPIES AGAINST CANCER
CN101643496B (zh) * 2008-08-07 2015-09-09 长春华普生物技术有限公司 一种具有免疫抑制功能的寡核苷酸
WO2010053433A1 (en) * 2008-11-04 2010-05-14 Index Pharmaceuticals Ab Increased expression of specific antigens
WO2012084991A1 (en) * 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Biologically active oligonucleotides capable of modulating the immune system ii
US9157919B2 (en) * 2010-12-21 2015-10-13 Index Pharmaceuticals Ab Method for identifying biologically active oligonucleotides capable of modulating the immune system
CN106893724B (zh) * 2015-12-17 2023-05-02 苏州派动生物技术有限公司 具有抗原增效作用和肿瘤治疗作用的寡核苷酸
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2024245358A1 (zh) 2023-05-30 2024-12-05 四川三叶草生物制药有限公司 冠状病毒疫苗组合物、方法及其使用
WO2024251281A1 (zh) 2023-06-07 2024-12-12 四川三叶草生物制药有限公司 Rsv疫苗组合物、方法及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
AU724133B2 (en) * 1997-02-12 2000-09-14 Chugai Seiyaku Kabushiki Kaisha Remedies for lymphocytic tumors
CZ301488B6 (cs) * 1999-09-25 2010-03-24 University Of Iowa Research Foundation Použití imunostimulacních nukleových kyselin
KR20020091170A (ko) * 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
CA2410371C (en) * 2000-06-22 2015-11-17 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US20040009156A1 (en) * 2001-10-12 2004-01-15 Christoph Reinhard Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
JP2005516917A (ja) 2001-12-12 2005-06-09 アメリカ合衆国 細胞外アデノシン阻害剤およびアデノシン受容体阻害剤を用いて免疫応答および炎症を増強するための方法
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
DE10258677A1 (de) 2002-12-13 2004-06-24 Elez, Vera, Dr. Kombinations-antisense-Oligonukleotid-Krebstherapie
CN100439386C (zh) * 2003-03-05 2008-12-03 长春华普生物技术有限公司 增强蛋白类疫苗免疫效果的含CpG单链脱氧寡核苷酸
CN100486987C (zh) * 2003-03-05 2009-05-13 长春华普生物技术有限公司 抗病毒和抗肿瘤的含CpG单链脱氧寡核苷酸
DE10333509B4 (de) * 2003-07-18 2007-05-03 Technische Universität Dresden Gegen VEGF gerichtete Erkennungsmoleküle und die Verwendung dieser
CA2533434C (en) 2003-07-25 2011-07-05 Changchun Huapu Biotechnology Co., Ltd. Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof
JP4513879B2 (ja) 2008-03-05 2010-07-28 ソニー株式会社 像ぶれ補正装置、レンズ鏡筒装置及びカメラ装置

Also Published As

Publication number Publication date
IL187281A0 (en) 2011-08-01
CA2609067A1 (en) 2006-11-23
JP2008539768A (ja) 2008-11-20
RU2007146705A (ru) 2009-06-27
PT1883411E (pt) 2013-11-11
SI1883411T1 (sl) 2014-01-31
BRPI0609882A2 (pt) 2010-05-04
EP1883411A1 (en) 2008-02-06
JP4837034B2 (ja) 2011-12-14
IL187281A (en) 2012-04-30
RU2007146706A (ru) 2009-06-27
US20120142761A1 (en) 2012-06-07
US8133874B2 (en) 2012-03-13
DK1883647T3 (da) 2014-01-27
WO2006122464A1 (en) 2006-11-23
BRPI0609885A2 (pt) 2010-05-04
KR101294131B1 (ko) 2013-08-07
WO2006122463A1 (en) 2006-11-23
CN1865275B (zh) 2011-06-15
KR101346716B1 (ko) 2014-01-02
EP1883647A1 (en) 2008-02-06
IL187249A (en) 2012-03-29
ZA200710312B (en) 2009-08-26
EP1883647A4 (en) 2010-10-06
PT1883647E (pt) 2014-01-20
EP1883411B1 (en) 2013-08-14
AU2006246897A1 (en) 2006-11-23
CN1865275A (zh) 2006-11-22
CY1114844T1 (el) 2016-12-14
HK1112745A1 (en) 2008-09-12
EP1883647B1 (en) 2013-10-23
ES2433129T3 (es) 2013-12-09
IL187249A0 (en) 2008-02-09
ES2442462T3 (es) 2014-02-11
KR20080007655A (ko) 2008-01-22
NZ563582A (en) 2010-04-30
HK1113318A1 (en) 2008-10-03
RU2409672C2 (ru) 2011-01-20
UA91057C2 (ru) 2010-06-25
JP2008539767A (ja) 2008-11-20
US20090202567A1 (en) 2009-08-13
JP4837033B2 (ja) 2011-12-14
MX2007014145A (es) 2008-03-07
DK1883411T3 (da) 2013-11-18
CA2609062A1 (en) 2006-11-23
PL1883411T3 (pl) 2014-01-31
RU2413519C2 (ru) 2011-03-10
US20090162279A1 (en) 2009-06-25
AU2006246897B2 (en) 2012-04-12
SI1883647T1 (sl) 2014-02-28
EP1883411A4 (en) 2010-10-06
MX2007014146A (es) 2008-03-07
US8450292B2 (en) 2013-05-28
CA2609062C (en) 2013-11-19
ZA200710311B (en) 2009-08-26
PL1883647T3 (pl) 2014-03-31
AU2006246898B2 (en) 2011-08-18
KR20080011426A (ko) 2008-02-04
AU2006246898A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
NZ591416A (en) Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
MX2008007286A (es) Ingenieria in vivo de superficie celular.
MX2007012237A (es) Amilina y agonistas de amilina para tratar enfermedades y trastornos siquiatricos.
WO2004076644A3 (en) A composition for delivering an agent to a target cell and uses thereof
ES2619332T3 (es) Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
WO2009014903A3 (en) Colouring solution for dental ceramic articles and related methods
TW200518769A (en) Use of calcitonin in osteoarthritis
TW200714283A (en) Method and composition for treating peripheral vascular diseases
MX2009004986A (es) Metodos de tratamiento de anemia hemolitica.
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
MX2009008270A (es) Polipeptido novedoso que tiene actividad anti-tumoral.
AU5392001A (en) Taci as an anti-tumor agent
MX2008012748A (es) Un proceso para la concentracion de un polipeptido.
MX2013006266A (es) Articulo que se puede eliminar con agua que incluye un aglutinante poliuretanico y metodo de uso de este.
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
UA94231C2 (ru) Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли
WO2006134190A8 (es) Agentes y métodos basados en el uso del dominio eda de la fibronectina
TW200602076A (en) O, O'-amidomalonate and N, O-amidomalonate platinum complexes
MX2009003022A (es) Composiciones y metodos para tratar picaduras de medusa.
WO2007018671A3 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
WO2005116252A8 (en) Methods for evaluating ribonucleotide sequences
WO2006128089A3 (en) Compositions and methods for treating tissue
MX2010010177A (es) Fragmentos de beta timosina mejorada.
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
MX2007000364A (es) Metodos para tratar cancer usando agentes que inhiben la senalizacion de wnt16.